
  
    
      
        Background_NNP
        Patients_NNS with_IN Alzheimer_NNP 's_POS disease_NN experience_NN a_DT
        progressive_JJ cognitive_JJ loss_NN leading_VBG to_TO increasingly_RB shorter_JJR
        periods_NNS during_IN which_WDT they_PRP can_MD safely_RB be_VB left_VBN alone_RB and_CC to_TO
        dependence_NN on_IN their_PRP$ caregivers_NNS for_IN help_NN with_IN the_DT activities_NNS
        of_IN daily_JJ life_NN [_NN 1_CD 2_CD 3_CD 4_CD 5_CD ]_NN ._. The_DT Mini-_NNP Mental_NNP State_NNP
        Examination_NNP (_( MMSE_NNP )_) [_NN 6_CD ]_NN is_VBZ commonly_RB used_VBN in_IN clinical_JJ
        practice_NN to_TO assess_VB cognition_NN ,_, whereas_IN in_IN research_NN ,_, the_DT
        cognitive_JJ part_NN of_IN the_DT Alzheimer_NNP 's_POS Disease_NNP Assessment_NNP Scale_NNP
        (_( ADAS-cog_NNP )_) [_NN 7_CD ]_NN predominates_NNS ._. There_EX is_VBZ ,_, therefore_RB ,_,
        interest_NN in_IN how_WRB cognitive_JJ function_NN observed_VBD for_IN patients_NNS in_IN
        clinical_JJ trials_NNS compares_VBZ with_IN the_DT results_NNS from_IN clinical_JJ
        practice_NN and_CC the_DT likely_JJ effects_NNS on_IN patients_NNS '_POS wider_JJR
        functioning_VBG [_NN 8_CD ]_NN ._.
        In_IN this_DT study_NN ,_, we_PRP investigated_VBD the_DT relationship_NN of_IN
        patients_NNS '_POS cognitive_JJ function_NN to_TO dependence_NN on_IN caregivers_NNS
        before_IN the_DT patients_NNS reach_VBP a_DT severe_JJ stage_NN of_IN the_DT disease_NN ._.
        Cognitive_NNP function_NN was_VBD assessed_VBN with_IN both_DT the_DT ADAS-cog_NNP and_CC
        the_DT MMSE_NNP ._. Our_PRP$ analyses_NNS employed_VBN three_CD different_JJ definitions_NNS
        of_IN dependence_NN ._. In_IN one_CD approach_NN ,_, caregivers_NNS assessed_VBD the_DT
        number_NN of_IN hours_NNS of_IN supervision_NN patients_NNS required_VBD each_DT day_NN ,_,
        in_IN another_DT patients_NNS were_VBD assigned_VBN a_DT level_NN of_IN dependence_NN
        based_VBN on_IN their_PRP$ care_NN needs_VBZ [_NN 9_CD ]_NN ,_, and_CC in_IN the_DT third_JJ ,_,
        caregivers_NNS were_VBD asked_VBN questions_NNS about_IN the_DT patients_NNS '_POS ability_NN
        to_TO independently_RB perform_VB activities_NNS of_IN daily_JJ living_NN that_WDT
        had_VBD been_VBN attempted_VBN in_IN the_DT preceding_VBG two_CD weeks_NNS [_NN 10_CD ]_NN ._.
        In_IN a_DT clinical_JJ setting_NN ,_, MMSE_NNP scores_NNS are_VBP frequently_RB
        available_JJ ,_, and_CC conversions_NNS of_IN cognitive_JJ scale_NN scores_NNS from_IN
        one_CD to_TO the_DT other_JJ have_VBP been_VBN proposed_VBN [_NN 11_CD 12_CD ]_NN ._. One_CD aspect_NN
        of_IN this_DT study_NN evaluates_VBZ whether_IN it_PRP is_VBZ reasonable_JJ to_TO convert_VB
        MMSE_NNP to_TO ADAS-cog_NNP and_CC predict_VBP dependence_NN based_VBN on_IN the_DT
        converted_VBN score_NN ._. The_DT reasonableness_NNS of_IN doing_VBG this_DT is_VBZ judged_VBN
        based_VBN on_IN how_WRB similar_JJ the_DT results_NNS are_VBP to_TO what_WP would_MD be_VB
        obtained_VBN if_IN a_DT subject_NN 's_POS actual_JJ ADAS-cog_NNP score_NN were_VBD
        known_VBN ._.
      
      
        Methods_NNP
        
          Data_NNP sources_NNS
          Data_NNP were_VBD obtained_VBN on_IN 1_CD ,_, 289_CD patients_NNS diagnosed_VBN with_IN
          mild-to-moderate_JJ Alzheimer_NNP 's_POS disease_NN studied_VBD in_IN two_CD
          randomised_JJ clinical_JJ trials_NNS of_IN galantamine_NN (_( Reminyl_NNP Â®_NN )_) [_NN
          13_CD 14_CD ]_NN ._. This_DT is_VBZ a_DT post-hoc_JJ analysis_NN employing_VBG data_NNS
          obtained_VBN from_IN patients_NNS '_POS baseline_NN visits_NNS ,_, before_IN they_PRP
          began_VBD treatment_NN in_IN the_DT trials_NNS ._. All_DT patients_NNS enrolled_VBD in_IN
          these_DT trials_NNS were_VBD diagnosed_VBN with_IN Alzheimer_NNP 's_POS disease_NN
          according_VBG to_TO NINCDS-ADRDA_NNP classification_NN [_NN 15_CD ]_NN ._. The_DT
          patients_NNS had_VBD a_DT mild-to-moderate_JJ disease_NN (_( MMSE_NNP scores_NNS
          10_CD -_: 24_CD )_) with_IN a_DT history_NN of_IN cognitive_JJ decline_NN ,_, gradual_JJ
          onset_NN ,_, and_CC progressive_JJ disease_NN over_IN a_DT period_NN of_IN at_IN least_JJS
          six_CD months_NNS ._. Cognitive_NNP function_NN was_VBD assessed_VBN using_VBG both_DT
          the_DT ADAS-cog_NNP and_CC MMSE_NNP scales_NNS ._. Caregivers_NNP of_IN the_DT patients_NNS
          included_VBN in_IN these_DT analyses_NNS agreed_VBD to_TO participate_VB in_IN the_DT
          trial_NN ._.
        
        
          Dependence_NNP
          Dependence_NNP was_VBD measured_VBN using_VBG three_CD definitions_NNS
          derived_VBN from_IN the_DT hours_NNS of_IN supervision_NN needed_VBN from_IN a_DT
          caregiver_NN ,_, the_DT amount_NN of_IN care_NN needed_VBN and_CC the_DT patient_NN 's_POS
          ability_NN to_TO carry_VB out_RP the_DT activities_NNS of_IN daily_JJ life_NN ._.
          The_DT caregivers_NNS were_VBD asked_VBN to_TO assess_VB whether_IN the_DT
          patient_NN required_VBD 24_CD -_: hour_NN supervision_NN ,_, and_CC if_IN this_DT was_VBD not_RB
          considered_VBN necessary_JJ ,_, caregivers_NNS reported_VBD the_DT number_NN of_IN
          hours_NNS the_DT patient_NN could_MD be_VB left_VBN alone_RB each_DT day_NN ._. From_IN
          these_DT data_NNS ,_, the_DT amount_NN of_IN supervision_NN time_NN required_VBN by_IN a_DT
          patient_NN during_IN the_DT course_NN of_IN a_DT day_NN was_VBD derived_VBN ._. Patients_NNS
          were_VBD considered_VBN to_TO have_VB become_VBN dependent_JJ on_IN caregivers_NNS if_IN
          the_DT caregivers_NNS reported_VBD that_IN they_PRP required_VBD more_JJR than_IN
          twelve_CD hours_NNS of_IN supervision_NN each_DT day_NN ._.
          Patients_NNS '_POS care_NN needs_NNS were_VBD recorded_VBN using_VBG an_DT instrument_NN
          that_WDT was_VBD developed_VBN and_CC validated_JJ specifically_RB to_TO assess_VB
          dependency_NN of_IN patients_NNS with_IN Alzheimer_NNP 's_POS disease_NN [_NN 9_CD ]_NN ._.
          This_DT dependence_NN scale_NN was_VBD designed_VBN to_TO assess_VB levels_NNS of_IN
          need_VBP and_CC therefore_RB the_DT care_NN expected_VBN to_TO be_VB required_VBN ,_, as_IN a_DT
          result_NN of_IN the_DT loss_NN of_IN cognitive_JJ and_CC functional_JJ skills_NNS
          typically_RB observed_VBD in_IN patients_NNS with_IN Alzheimer_NNP 's_POS disease_NN ._.
          Each_DT caregiver_NN was_VBD asked_VBN thirteen_NN questions_NNS about_IN the_DT
          type_NN of_IN care_NN the_DT patient_NN required_VBN ._. Depending_VBG on_IN the_DT
          responses_NNS ,_, patients_NNS were_VBD assigned_VBN to_TO one_CD of_IN six_CD levels_NNS of_IN
          dependency_NN ,_, with_IN level_NN zero_CD representing_VBG independence_NN and_CC
          level_NN five_CD the_DT highest_JJS level_NN of_IN dependence_NN ._. Items_NNS in_IN
          level_NN three_CD and_CC above_IN indicate_VBP that_IN patients_NNS need_VBP
          supervision_NN and_CC assistance_NN with_IN common_JJ tasks_NNS ,_, for_IN example_NN
          they_PRP need_VBP to_TO be_VB watched_VBN when_WRB awake_JJ ,_, or_CC escorted_JJ when_WRB
          outside_IN ,_, or_CC accompanied_VBD when_WRB bathing_NN and_CC eating_VBG ._. Patients_NNS
          assigned_VBN to_TO dependency_NN levels_NNS of_IN three_CD or_CC higher_JJR were_VBD
          considered_VBN to_TO be_VB dependent_JJ ._.
          The_DT Disability_NNP Assessment_NNP for_IN Dementia_NNP (_( DAD_NNP )_) scale_NN was_VBD
          also_RB completed_VBN by_IN the_DT caregivers_NNS [_NN 10_CD ]_NN ._. This_DT instrument_NN
          was_VBD developed_VBN and_CC validated_JJ to_TO measure_VB the_DT functional_JJ
          disability_NN of_IN patients_NNS with_IN Alzheimer_NNP 's_POS disease_NN ._.
          Caregivers_NNP answered_VBD questions_NNS about_IN the_DT patients_NNS '_POS ability_NN
          to_TO independently_RB perform_VB both_DT instrumental_JJ and_CC basic_JJ
          activities_NNS of_IN daily_JJ living_NN that_WDT had_VBD been_VBN attempted_VBN in_IN the_DT
          preceding_VBG two_CD weeks_NNS ._. The_DT proportion_NN of_IN DAD_NNP activities_NNS
          successfully_RB completed_VBN out_IN of_IN those_DT attempted_VBN is_VBZ then_RB
          determined_VBN and_CC reported_VBN as_IN a_DT percentage_NN ._.
        
        
          Analyses_NNS
          Analyses_NNS were_VBD conducted_VBN separately_RB for_IN each_DT measure_NN of_IN
          dependence_NN ._. In_IN addition_NN to_TO the_DT two_CD measures_NNS of_IN cognitive_JJ
          functioning_NN ,_, age_NN ,_, gender_NN ,_, time_NN since_IN onset_NN of_IN cognitive_JJ
          problems_NNS ,_, use_NN of_IN antipsychotic_JJ medication_NN ,_, presence_NN of_IN
          extrapyramidal_NN symptoms_NNS ,_, and_CC living_VBG situation_NN were_VBD
          considered_VBN as_IN potential_JJ predictors_NNS ._. Since_IN the_DT MMSE_NNP and_CC
          ADAS-cog_NNP are_VBP correlated_JJ ,_, separate_JJ models_NNS were_VBD constructed_VBN
          for_IN each_DT of_IN the_DT outcomes_NNS using_VBG each_DT cognitive_JJ scale_NN
          alone_RB ._.
          The_DT relation_NN of_IN the_DT two_CD dichotomous_JJ dependence_NN
          outcomes_NNS (_( >_NN 12_CD hours_NNS supervision_NN and_CC dependence_NN
          level_NN >_NN =_SYM 3_LS )_) to_TO potential_JJ predictors_NNS ,_, including_VBG cognitive_JJ
          function_NN ,_, was_VBD investigated_VBN initially_RB in_IN bivariate_NN
          analyses_NNS ._. For_IN continuous_JJ predictors_NNS such_JJ as_IN MMSE_NNP and_CC
          ADAS-cog_NNP scores_NNS ,_, linearity_NN in_IN the_DT log_NN of_IN the_DT odds_NNS of_IN the_DT
          outcomes_NNS was_VBD verified_VBN over_IN subintervals_NNS of_IN the_DT
          predictors_NNS ._. For_IN categorical_JJ predictors_NNS such_JJ as_IN gender_NN ,_,
          the_DT odds_NNS ratio_NN was_VBD computed_JJ and_CC tested_VBN for_IN significance_NN ._.
          The_DT significant_JJ predictors_NNS were_VBD retained_VBN and_CC included_VBN in_IN
          a_DT logistic_JJ regression_NN model_NN to_TO estimate_VB the_DT odds_NNS ratio_NN
          for_IN being_VBG defined_VBN as_IN dependent_JJ ,_, and_CC to_TO measure_VB the_DT effect_NN
          of_IN cognitive_JJ function_NN ,_, adjusting_VBG for_IN other_JJ factors_NNS ._. A_DT
          stepwise_NN forward_RB procedure_NN was_VBD used_VBN to_TO identify_VB the_DT most_RBS
          important_JJ predictors_NNS ._.
          Due_JJ to_TO a_DT skewed_VBN spread_NN of_IN DAD_NNP scores_NNS over_IN its_PRP$ range_NN ,_, a_DT
          transformation_NN was_VBD required_VBN to_TO normalize_VB the_DT
          distribution_NN ._. Since_IN the_DT DAD_NNP is_VBZ scored_VBN as_IN a_DT proportion_NN ,_,
          the_DT recommended_VBN transformation_NN is_VBZ arcsin_NN (_( square_JJ root_NN
          (_( DAD_NNP )_) )_) ._. The_DT relation_NN of_IN the_DT transformed_VBN DAD_NNP scores_NNS to_TO the_DT
          predictors_NNS was_VBD determined_VBN using_VBG correlation_NN coefficients_NNS ,_,
          t-tests_JJ and_CC ANOVAs_NNP ._. Predictors_NNP were_VBD retained_VBN in_IN two_CD
          multivariate_NN regression_NN models_NNS to_TO investigate_VB the_DT
          relation_NN of_IN the_DT transformed_VBN DAD_NNP score_NN to_TO either_CC MMSE_NNP or_CC
          ADAS-cog_NNP score_NN and_CC other_JJ determinants_NNS ._. A_DT stepwise_NN forward_RB
          procedure_NN was_VBD used_VBN to_TO identify_VB statistically_RB significant_JJ
          predictors_NNS ._.
          We_PRP then_RB used_VBD these_DT models_NNS to_TO investigate_VB how_WRB well_RB MMSE_NNP
          values_NNS converted_VBN to_TO ADAS-cog_NNP predict_VBP dependence_NN compared_VBN
          to_TO predictions_NNS based_VBN on_IN the_DT actual_JJ ADAS-cog_NNP values_NNS ,_, after_IN
          adjusting_VBG for_IN other_JJ factors_NNS ._. The_DT MMSE_NNP scores_NNS were_VBD
          converted_VBN linearly_RB to_TO ADAS-cog_NNP values_NNS (_( a_DT decrease_NN of_IN 1_CD
          MMSE_NNP =_SYM an_DT increase_NN of_IN 2_CD ._. 33_CD ADAS-cog_NNP points_NNS ,_, or_CC ADAS-cog_NNP =_SYM
          70_CD -_: 2_CD ._. 33_CD *_NN MMSE_NNP )_) ._. For_IN each_DT patient_NN ,_, the_DT DAD_NNP score_NN was_VBD then_RB
          predicted_VBN based_VBN on_IN the_DT actual_JJ and_CC converted_VBN ADAS-cog_NNP
          scores_NNS ._. The_DT difference_NN between_IN the_DT two_CD predictions_NNS was_VBD
          used_VBN as_IN the_DT measure_NN of_IN agreement_NN ._. The_DT predicted_VBD DAD_NNP
          scores_NNS were_VBD then_RB compared_VBN to_TO each_DT other_JJ ._.
        
      
      
        Results_NNS
        The_DT socio-demographic_JJ and_CC clinical_JJ characteristics_NNS of_IN
        the_DT 1_CD ,_, 287_CD patients_NNS included_VBN in_IN these_DT analyses_NNS are_VBP
        summarized_VBD in_IN Table_NNP 1_CD ._. Two_CD patients_NNS were_VBD excluded_VBN from_IN the_DT
        analyses_NNS because_IN their_PRP$ MMSE_NNP score_NN was_VBD reported_VBN as_IN zero_CD ._. On_IN
        average_JJ ,_, caregivers_NNS reported_VBD that_IN their_PRP$ patients_NNS required_VBN
        about_IN 14_CD hours_NNS of_IN supervision_NN each_DT day_NN (_( SD_NNP 9_CD ._. 3_LS )_) ._. There_EX was_VBD
        considerable_JJ variation_NN in_IN the_DT responses_NNS ,_, as_IN 25_CD %_NN (_( N_NNP =_SYM 326_CD )_)
        were_VBD reported_VBN to_TO require_VB no_DT supervision_NN while_IN 15_CD %_NN (_( N_NNP =_SYM 188_CD )_)
        were_VBD felt_VBN to_TO require_VB 24_CD -_: hour_NN supervision_NN ._. Approximately_RB
        two-thirds_NNS required_VBD more_JJR than_IN 12_CD hours_NNS of_IN supervision_NN ,_, and_CC
        their_PRP$ mean_NN ADAS-cog_NNP ,_, MMSE_NNP ,_, and_CC DAD_NNP scores_NNS ,_, were_VBD
        significantly_RB worse_JJR than_IN those_DT of_IN patients_NNS who_WP were_VBD deemed_VBN
        less_RBR dependent_JJ ._.
        Overall_RB ,_, 46_CD %_NN of_IN patients_NNS were_VBD assigned_VBN to_TO the_DT dependent_JJ
        care_NN levels_NNS >_NN =_SYM 3_CD ,_, and_CC their_PRP$ mean_NN DAD_NNP score_NN was_VBD
        significantly_RB lower_JJR than_IN that_DT of_IN those_DT who_WP were_VBD less_RBR
        dependent_JJ (_( 56_CD %_NN vs_NNS ._. 82_CD %_NN ,_, t-test_JJ p_NN <_NN 0_CD ._. 0001_CD )_) ._.
        Antipsychotic_NNP medication_NN was_VBD prescribed_VBN to_TO 26_CD %_NN of_IN the_DT
        patients_NNS and_CC they_PRP too_RB had_VBD DAD_NNP scores_NNS lower_JJR than_IN patients_NNS
        not_RB prescribed_VBN antipsychotic_JJ medication_NN (_( 64_CD %_NN vs_NNS ._. 72_CD %_NN ,_,
        t-test_JJ ,_, p-value_JJ <_NN 0_CD ._. 001_CD )_) ._. Far_NNP fewer_JJR patients_NNS overall_RB had_VBD
        extrapyramidal_NN symptoms_NNS ,_, however_RB ,_, among_IN those_DT that_WDT did_VBD ,_, the_DT
        mean_NN DAD_NNP score_NN was_VBD lower_JJR than_IN for_IN those_DT without_IN symptoms_NNS
        (_( 62_CD %_NN vs_NNS 70_CD %_NN ,_, t-test_JJ ,_, p-value_JJ 0_CD ._. 0037_CD )_) ._.
        The_DT odds_NNS ratio_NN for_IN both_DT categorical_JJ measures_NNS of_IN
        dependence_NN was_VBD significantly_RB higher_JJR with_IN worse_RBR cognitive_JJ
        impairment_NN ,_, increasing_VBG with_IN each_DT detrimental_JJ point_NN change_NN
        in_IN ADAS-cog_NNP or_CC MMSE_NNP score_NN ,_, adjusting_VBG for_IN age_NN ,_, gender_NN and_CC
        use_NN of_IN antipsychotic_JJ medication_NN (_( Table_NNP 2_LS )_) ._. For_IN the_DT MMSE_NNP
        model_NN ,_, a_DT one-point_JJ difference_NN was_VBD associated_VBN with_IN an_DT
        increase_NN in_IN the_DT adjusted_VBN odds_NNS for_IN requiring_VBG >_NN 12_CD hours_NNS
        supervision_NN per_IN day_NN of_IN 13_CD %_NN (_( 95_CD %_NN CI_NNP 9_CD -_: 17_CD )_) and_CC for_IN dependence_NN
        level_NN >_NN =_SYM 3_CD of_IN 22_CD %_NN (_( 95_CD %_NN CI_NNP 18_CD -_: 27_CD )_) ._. A_DT one-point_JJ
        difference_NN of_IN the_DT ADAS-cog_NNP score_NN was_VBD associated_VBN with_IN an_DT
        increase_NN in_IN the_DT adjusted_VBN odds_NNS for_IN requiring_VBG >_NN 12_CD hours_NNS
        supervision_NN per_IN day_NN of_IN 4_CD %_NN (_( 95_CD %_NN CI_NNP 3_CD -_: 5_LS )_) and_CC for_IN dependence_NN
        level_NN >_NN =_SYM 3_CD of_IN 8_CD %_NN (_( 95_CD %_NN CI_NNP 6_CD -_: 9_CD )_) ,_, after_IN adjusting_VBG for_IN age_NN ,_,
        gender_NN and_CC use_NN of_IN antipsychotic_JJ medication_NN ._.
        For_IN predictions_NNS of_IN dependence_NN based_VBN on_IN transformed_VBN
        scores_NNS from_IN the_DT DAD_NNP two_CD separate_JJ models_NNS were_VBD developed_VBN ._. One_CD
        model_NN was_VBD based_VBN on_IN the_DT ADAS-cog_NNP and_CC the_DT second_NN on_IN the_DT MMSE_NNP
        (_( Table_NNP 3_LS )_) ._. In_IN each_DT case_NN ,_, the_DT cognitive_JJ score_NN was_VBD found_VBN to_TO
        be_VB a_DT strong_JJ predictor_NN of_IN dependence_NN ._. No_DT significant_JJ
        interaction_NN was_VBD present_JJ ._.
        Disability_NNP predicted_VBD directly_RB using_VBG the_DT actual_JJ ADAS-cog_NNP
        scores_NNS and_CC other_JJ patient_NN characteristics_NNS was_VBD compared_VBN to_TO
        prediction_NN based_VBN on_IN ADAS-cog_NNP scores_NNS converted_VBN from_IN MMSE_NNP
        scores_NNS ,_, adjusting_VBG for_IN other_JJ patient_NN characteristics_NNS ._. Figure_NN
        1_CD shows_VBZ a_DT summary_NN of_IN these_DT predictions_NNS ._. For_IN MMSE_NNP scores_NNS
        ranging_VBG from_IN 10_CD to_TO 24_CD ,_, we_PRP calculated_VBD the_DT average_NN predicted_VBD
        DAD_NNP using_VBG the_DT actual_JJ ADAS-cog_NNP scores_NNS (_( with_IN standard_JJ
        deviation_NN )_) ;_: the_DT corresponding_JJ values_NNS for_IN the_DT predictions_NNS
        with_IN converted_VBN values_NNS are_VBP also_RB shown_VBN ._. There_EX was_VBD a_DT close_JJ
        agreement_NN between_IN the_DT average_JJ predictions_NNS ._. For_IN example_NN ,_, our_PRP$
        sample_NN contained_VBD 91_CD subjects_NNS with_IN baseline_NN MMSE_NNP score_NN of_IN
        20_CD ;_: the_DT average_JJ ADAS-cog_NNP score_NN for_IN these_DT patients_NNS was_VBD 24_CD ._. 2_LS ,_,
        which_WDT is_VBZ reasonably_RB close_RB to_TO the_DT converted_VBN value_NN of_IN 23_CD ._. 4_LS ._.
        The_DT average_JJ DAD_NNP score_NN predicted_VBD from_IN the_DT actual_JJ ADAS-cog_NNP
        scores_NNS was_VBD 74_CD %_NN with_IN a_DT standard_JJ deviation_NN of_IN 10_CD %_NN ._. The_DT
        average_NN of_IN predictions_NNS made_VBN with_IN converted_VBN scores_NNS and_CC other_JJ
        patient_NN 's_POS characteristics_NNS was_VBD 76_CD %_NN (_( SD_NNP =_SYM 4_CD ._. 9_CD %_NN )_) ,_, for_IN a_DT
        difference_NN of_IN 1_CD ._. 4_CD %_NN ._. Similarly_RB ,_, the_DT average_JJ difference_NN in_IN
        predictions_NNS for_IN other_JJ MMSE_NNP scores_NNS were_VBD also_RB reasonably_RB
        small_JJ ,_, ranging_VBG from_IN -_: 1_CD ._. 5_LS %_NN to_TO 3_CD ._. 1_CD %_NN ,_, equivalent_JJ to_TO less_JJR than_IN
        a_DT single_JJ activity_NN on_IN the_DT DAD_NNP ._.
      
      
        Discussion_NNP
        The_DT loss_NN of_IN a_DT patient_NN 's_POS ability_NN to_TO independently_RB perform_VB
        daily_JJ activities_NNS is_VBZ an_DT important_JJ aspect_NN of_IN Alzheimer_NNP 's_POS for_IN
        patients_NNS and_CC their_PRP$ families_NNS ,_, and_CC for_IN health_NN care_NN
        decision-makers_NNS ._. Our_PRP$ study_NN has_VBZ demonstrated_VBN that_IN relatively_RB
        small_JJ degrees_NNS of_IN loss_NN of_IN cognitive_JJ skills_NNS in_IN patients_NNS at_IN
        the_DT mild-to-moderate_JJ stages_NNS of_IN the_DT disease_NN leads_VBZ to_TO an_DT
        increased_VBN risk_NN of_IN losing_VBG the_DT ability_NN to_TO live_VB independently_RB ._.
        In_IN our_PRP$ study_NN of_IN patients_NNS recruited_VBN for_IN clinical_JJ trials_NNS at_IN
        the_DT mild-to-moderate_JJ stage_NN ,_, 69_CD %_NN already_RB required_VBD more_JJR than_IN
        12_CD hours_NNS of_IN supervision_NN per_IN day_NN ._. This_DT is_VBZ consistent_JJ with_IN
        other_JJ studies_NNS ,_, which_WDT have_VBP shown_VBN that_IN sometimes_RB a_DT dependent_JJ
        stage_NN is_VBZ reached_VBN quite_RB early_RB in_IN the_DT disease_NN ,_, when_WRB
        caregivers_NNS decide_VBP that_IN the_DT patients_NNS can_MD no_RB longer_RB be_VB left_VBN
        alone_RB safely_RB [_NN 3_CD 16_CD 17_CD ]_NN ._.
        A_DT three-point_JJ difference_NN in_IN MMSE_NNP score_NN was_VBD associated_VBN
        with_IN an_DT increase_NN in_IN the_DT adjusted_VBN odds_NNS of_IN requiring_VBG more_JJR
        than_IN 12_CD hours_NNS of_IN supervision_NN of_IN 43_CD %_NN at_IN the_DT time_NN of_IN the_DT
        assessment_NN ;_: and_CC if_IN dependence_NN is_VBZ measured_VBN as_IN level_NN three_CD or_CC
        higher_JJR ,_, the_DT odds_NNS increase_VBP by_IN 82_CD %_NN ,_, even_RB after_IN adjusting_VBG for_IN
        age_NN ,_, gender_NN and_CC use_NN of_IN antipsychotic_JJ medication_NN ._. Similarly_RB ,_,
        a_DT 4_CD -_: point_NN difference_NN in_IN ADAS-cog_NNP score_NN is_VBZ associated_VBN with_IN
        an_DT increase_NN in_IN the_DT adjusted_VBN odds_NNS for_IN requiring_VBG more_JJR than_IN 12_CD
        hours_NNS of_IN supervision_NN of_IN 17_CD %_NN ,_, and_CC 35_CD %_NN for_IN having_VBG a_DT
        dependence_NN level_NN greater_JJR than_IN two_CD ._. The_DT very_RB comprehensive_JJ
        measures_NNS of_IN dependence_NN collected_VBN at_IN the_DT start_NN of_IN these_DT
        trials_NNS allowed_VBD us_PRP to_TO evaluate_VB the_DT association_NN of_IN dependence_NN
        with_IN a_DT patient_NN 's_POS cognitive_JJ functioning_NN at_IN that_DT point_NN in_IN
        time_NN ._. It_PRP is_VBZ important_JJ to_TO note_VB that_IN since_IN this_DT is_VBZ a_DT
        cross-sectional_JJ study_NN we_PRP could_MD not_RB investigate_VB the_DT extent_NN
        to_TO which_WDT decreases_NNS or_CC improvements_NNS in_IN cognitive_JJ function_NN
        would_MD be_VB associated_VBN with_IN changes_NNS in_IN dependence_NN over_IN
        time_NN ._.
        Behavioral_NNP disturbances_NNS are_VBP common_JJ amongst_IN patients_NNS with_IN
        Alzheimer_NNP 's_POS disease_NN [_NN 18_CD ]_NN and_CC antipsychotic_JJ medications_NNS
        were_VBD prescribed_VBN for_IN about_IN one-quarter_NN of_IN the_DT patients_NNS in_IN
        our_PRP$ study_NN ._. Antipsychotic_NNP medication_NN use_NN was_VBD also_RB
        consistently_RB found_VBD to_TO be_VB a_DT predictor_NN of_IN having_VBG an_DT increased_VBN
        risk_NN of_IN disability_NN ,_, regardless_RB of_IN how_WRB dependence_NN was_VBD
        measured_VBN ._. This_DT is_VBZ consistent_JJ with_IN other_JJ studies_NNS ,_, which_WDT
        found_VBD that_IN patients_NNS using_VBG antipsychotic_JJ agents_NNS [_NN 19_CD ]_NN or_CC
        displaying_VBG psychotic_JJ symptoms_NNS [_NN 1_CD 19_CD 20_CD 21_CD ]_NN are_VBP more_RBR
        likely_JJ to_TO experience_VB a_DT faster_RBR functional_JJ decline_NN ._. Very_RB few_JJ
        patients_NNS in_IN our_PRP$ study_NN had_VBD extra-pyramidal_JJ symptoms_NNS ;_: it_PRP is_VBZ
        therefore_RB difficult_JJ to_TO interpret_VB their_PRP$ meaning_VBG with_IN
        certainty_NN ._. Other_JJ published_VBN studies_NNS however_RB ,_, have_VBP linked_VBN
        these_DT symptoms_NNS with_IN greater_JJR functional_JJ decline_NN [_NN 1_CD 20_CD 21_CD ]_NN
        ._.
        One_CD limitation_NN of_IN this_DT study_NN is_VBZ that_IN these_DT data_NNS were_VBD
        collected_VBN from_IN patients_NNS enrolled_VBD in_IN clinical_JJ trials_NNS ,_, and_CC
        therefore_RB our_PRP$ sample_NN may_MD not_RB be_VB representative_NN of_IN patients_NNS
        routinely_RB treated_VBN in_IN clinical_JJ practice_NN ._. Nevertheless_RB ,_, these_DT
        data_NNS provide_VBP a_DT unique_JJ opportunity_NN for_IN analyses_NNS as_IN
        information_NN was_VBD collected_VBN using_VBG both_DT the_DT MMSE_NNP and_CC ADAS-cog_NNP
        scales_NNS ,_, and_CC three_CD measures_NNS of_IN dependence_NN ._.
        Both_DT the_DT instruments_NNS used_VBN to_TO measure_VB dependence_NN in_IN this_DT
        study_NN had_VBD been_VBN developed_VBN and_CC validated_JJ specifically_RB for_IN use_NN
        in_IN patients_NNS with_IN Alzheimer_NNP 's_POS disease_NN [_NN 9_CD 10_CD ]_NN ._. The_DT
        dependence_NN scale_NN was_VBD designed_VBN to_TO assess_VB the_DT care_NN needs_NNS of_IN
        patients_NNS and_CC the_DT DAD_NNP scale_NN to_TO measure_VB functional_JJ
        disability_NN ._. Both_DT instruments_NNS were_VBD developed_VBN to_TO avoid_VB some_DT
        of_IN the_DT common_JJ problems_NNS observed_VBD with_IN other_JJ measures_NNS of_IN
        functional_JJ decline_NN ,_, such_JJ as_IN whether_IN certain_JJ instrumental_JJ
        activities_NNS of_IN daily_JJ living_NN had_VBN ever_RB been_VBN performed_VBN by_IN the_DT
        patient_NN [_NN 23_CD ]_NN ._. Our_PRP$ results_NNS were_VBD consistent_JJ between_IN the_DT
        models_NNS as_IN the_DT same_JJ predictors_NNS of_IN dependence_NN were_VBD found_VBN to_TO
        be_VB important_JJ regardless_RB of_IN how_WRB dependence_NN was_VBD measured_VBN ._.
        The_DT MMSE_NNP is_VBZ convenient_JJ to_TO administer_VB and_CC practical_JJ to_TO
        use_VB during_IN a_DT routine_JJ clinic_NN visit_NN ,_, but_CC clinical_JJ trials_NNS
        conducted_VBN to_TO study_VB treatments_NNS for_IN Alzheimer_NNP 's_POS disease_NN have_VBP
        primarily_RB used_VBN ADAS-cog_NNP as_IN the_DT measure_NN of_IN cognition_NN ._. This_DT
        study_NN indicates_VBZ that_IN it_PRP is_VBZ reasonable_JJ to_TO convert_VB MMSE_NNP to_TO
        ADAS-cog_NNP and_CC predict_VBP dependence_NN based_VBN on_IN the_DT converted_VBN
        score_NN ._. Our_PRP$ study_NN suggests_VBZ ,_, that_IN in_IN clinical_JJ practice_NN a_DT
        conversion_NN that_WDT assumes_VBZ one_CD MMSE_NNP point_NN is_VBZ equivalent_JJ to_TO
        2_CD ._. 33_CD ADAS-cog_NNP points_NNS (_( or_CC ADAS-cog_NNP =_SYM 70_CD -_: 2_CD ._. 33_CD *_NN MMSE_NNP )_) will_MD
        yield_VB a_DT reasonably_RB accurate_JJ estimate_NN of_IN disability_NN for_IN
        patients_NNS at_IN the_DT mild-to-moderate_JJ stages_NNS ._. This_DT is_VBZ also_RB
        consistent_JJ with_IN the_DT findings_NNS in_IN another_DT study_NN (_( ADAS-cog_NNP =_SYM
        72_CD ._. 2_LS -_: 2_CD ._. 41_CD *_NN MMSE_NNP )_) [_NN 11_CD ]_NN ._. If_IN its_PRP$ relation_NN to_TO dependence_NN is_VBZ
        the_DT main_JJ reason_NN to_TO measure_VB cognition_NN ,_, then_RB clinicians_NNS can_MD
        be_VB reassured_VBN about_IN these_DT conversions_NNS ._.
      
      
        Conclusions_NNP
        In_IN our_PRP$ study_NN ,_, patients_NNS who_WP had_VBD relatively_RB small_JJ degrees_NNS
        of_IN greater_JJR loss_NN of_IN cognitive_JJ function_NN ,_, whether_IN measured_VBN
        using_VBG either_CC the_DT ADAS-cog_NNP or_CC MMSE_NNP ,_, did_VBD appear_VB to_TO be_VB at_IN
        increased_VBN risk_NN of_IN being_VBG dependent_JJ on_IN caregivers_NNS ._.
        Understanding_NNP the_DT relationship_NN between_IN a_DT patient_NN 's_POS current_JJ
        cognitive_JJ status_NN ,_, current_JJ therapies_NNS and_CC their_PRP$ need_NN for_IN care_NN
        may_MD assist_VB clinicians_NNS in_IN the_DT management_NN of_IN patients_NNS
        diagnosed_VBN with_IN Alzheimer_NNP 's_POS disease_NN ._. Moreover_RB ,_, this_DT
        information_NN can_MD facilitate_VB discussions_NNS and_CC planning_NN with_IN
        caregivers_NNS ._. Future_JJ studies_NNS conducted_VBN to_TO evaluate_VB these_DT
        relationships_NNS longitudinally_RB can_MD further_RB inform_VB our_PRP$
        understanding_NN of_IN the_DT relationship_NN between_IN cognitive_JJ
        function_NN and_CC dependence_NN ._.
      
      
        Competing_VBG interests_NNS
        Caro_NNP Research_NNP of_IN which_WDT Jaime_NNP Caro_NNP is_VBZ a_DT shareholder_NN ,_,
        received_VBD a_DT grant_NN from_IN Janssen_NNP Research_NNP Foundation_NNP ,_, Beerse_NNP ,_,
        Belgium_NNP ,_, which_WDT provided_VBD funding_NN for_IN portions_NNS of_IN the_DT study_NN ._.
        No_DT editorial_NN control_NN was_VBD allowed_VBN ._.
        At_IN the_DT time_NN of_IN the_DT study_NN ,_, George_NNP Papadopoulos_NNP and_CC Koen_NNP
        Torfs_NNP were_VBD employed_VBN by_IN Janssen_NNP ,_, which_WDT provided_VBD funding_NN for_IN
        portions_NNS of_IN the_DT study_NN ._.
      
      
        Authors_NNP '_'' contributions_NNS
        JJC_NNP conceived_VBD of_IN and_CC designed_VBD the_DT study_NN ,_, and_CC
        participated_VBD in_IN drafting_VBG the_DT manuscript_NN ._. AW_NNP designed_VBD the_DT
        study_NN and_CC the_DT analysis_NN plan_NN ,_, and_CC drafted_VBD the_DT manuscript_NN ._. KI_NNP
        participated_VBD in_IN the_DT design_NN of_IN the_DT analysis_NN plan_NN ,_, conducted_VBN
        and_CC reported_VBN the_DT analyses_NNS ._. KMW_NNP participated_VBD in_IN the_DT design_NN
        of_IN the_DT study_NN and_CC the_DT drafting_VBG of_IN the_DT manuscript_NN ._. DG_NNP
        participated_VBD in_IN the_DT conception_NN ,_, design_NN and_CC analyses_NNS of_IN the_DT
        study_NN ._. GP_NNP participated_VBD in_IN the_DT study_NN design_NN and_CC development_NN
        of_IN the_DT analysis_NN plan_NN for_IN the_DT study_NN ._. KT_NNP participated_VBD in_IN the_DT
        conception_NN and_CC design_NN of_IN the_DT study_NN ._.
        All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
